Solutio™ catheter

CAUTION: For investigational use only. The Solutio catheter has not been evaluated by the FDA and is not available for sale in the USA.

Latest news

MedVasc Selected to Present at Prestigious MedTech Pitch Day by HGTF 2025

May 7, 2025
One of Only 10 Startups Chosen from 86 Applicants to Pitch Before Leading Central European MedTech Investors Lund, Sweden, May 6, 2025 – MedVasc…

MedVasc raises SEK 10 Million to accelerate final development and FDA preparation for Solutio™ device

May 7, 2025
Lund, Sweden – May 6, 2025 – MedVasc AB, a Swedish medical technology company  announces the successful closing of a SEK 10 million financing round…

Dr. Michael Åkesson featured on stage at the American Venous Forum, Atlanta

May 7, 2025
Our founder Dr. Michael Åkesson was invited to present the results from our first-in-man clinical study at the American Venous Forum in Athens in…

Changing the anesthesia procedure

With only one injection, instead of several injections through the skin, the Solutio catheter deploys local anesthesia from inside the vein, making the anesthesia procedure less painful for the patient, and more efficient for the clinician. The technology is developed from a clinical need and our first-in-man proved Solutio to be safe to use while significantly lowering pain in the process of deploying local anesthesia prior to performing thermal ablation of varicose veins. The Solutio catheter is compatible with a vast amount of treatment catheters in the market.

The Solutio catheter

Be the first one to try the Solutio catheter, sign up to get more information.

Based on years of experience

MedVasc AB was founded in 2013 by Michael Åkesson and has during the last years, developed a final prototype, been granted patents and trademarks in all prioritized markets, and performed a first-in-man clinical study. During 2023 MedVasc have initiated the FDA 510k process to gain a regulatory pathway towards FDA clearance.

Dr. Michael Åkesson – Board Member, Founder and CMO